Medtronic Inc. received FDA clearance of the Reveal DX Insertable Cardiac Monitor (ICM) designed to help physicians identify the cause of unexplained fainting or abnormal heart rhythms, including ventricular tachyarrhythmias (VT), fast ventricular tachyarrhythmias (FVT), bradyarrhythmias and asystole.

CardioDynamics recently received market clearance from the FDA for its BioZ Impedance Cardiography (ICG) clinical parameters and electronic medical record (EMR) interface capability for its BioZ Dx System.

A new 320-slice computed tomography (CT) system, the AquilionONE by Toshiba America Medical Systems, delivers dynamic volume imaging that can image an entire organ in a single rotation or over multiple rotations, showing real-time dynamic movement.
Multiphase studies, such as perfusion of the brain, heart and other organs, are also possible with the new system.

February 4, 2008 - The Centers for Medicare & Medicaid Services (CMS) announced that after completing a review of its 1986 national non-coverage policy for artificial hearts, its preliminary decision is to provide reimbursement for patients who receive the CardioWest temporary Total Artificial Heart (TAH-t) as part of FDA studies that meet CMS specifications.

February 4, 2008 – Fluke Biomedical unveiled today new defibrillator and pacemaker analyzer technologies, the Impulse 6000D Defibrillator Analyzer and the Impulse 7000DP Defibrillator/Pacer Analyzer, which are designed to be rugged, portable test instrumentation for biomedical technical professionals to ensure proper operation and ultimate performance of critical life-support cardiac resuscitati

Fluke Biomedical's product line of defibrillator and pacemaker analyzer technologies includes the Impulse 6000D Defibrillator Analyzer and the Impulse 7000DP Defibrillator/Pacer Analyzer, which are designed to be rugged, portable test instrumentation for biomedical technical professionals to ensure proper operation and ultimate performance of critical life-support cardiac resuscitation equipment.

February 4, 2008 - Heart conditions cost $76 billion to treat in 2005, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

February 1, 2008 - Medtronic Inc. has received approval from the FDA for the Endeavor Zotarolimus-Eluting Coronary Stent System to be used in the treatment of coronary artery disease.

February 1, 2008 - Medical Ventures Corp. signed an agreement to acquire two vascular product development companies, which the company expects will bring several new vascular therapies into its product pipeline and provide short and long-term revenue opportunities.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now